POST-KALA-AZAR DERMAL LEISHMANIASIS
Clinical trials for POST-KALA-AZAR DERMAL LEISHMANIASIS explained in plain language.
Never miss a new study
Get alerted when new POST-KALA-AZAR DERMAL LEISHMANIASIS trials appear
Sign up with your email to follow new studies for POST-KALA-AZAR DERMAL LEISHMANIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Old drug, new target: can ivermectin cure a stubborn skin parasite?
Disease control CompletedThis study tested if the drug ivermectin, taken by mouth, is a safe and effective treatment for Post-Kala-Azar Dermal Leishmaniasis (PKDL), a skin disease caused by parasites. It compared ivermectin given over three months to the standard 12-week miltefosine treatment in 30 patie…
Matched conditions: POST-KALA-AZAR DERMAL LEISHMANIASIS
Phase: EARLY_PHASE1 • Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Common drug tested for stubborn skin disease
Disease control CompletedThis small, early study tested if the drug ivermectin, taken by mouth, is safe and can help treat Post Kala-Azar Dermal Leishmaniasis (PKDL). PKDL is a skin condition that can appear after someone recovers from kala-azar (visceral leishmaniasis). The study involved 10 participant…
Matched conditions: POST-KALA-AZAR DERMAL LEISHMANIASIS
Phase: EARLY_PHASE1 • Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC